{"id":"roxadustat","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Thyroid hormone receptor beta","category":"target"},{"label":"THRB","category":"gene"},{"label":"THRA","category":"gene"},{"label":"EGLN2","category":"gene"},{"label":"B03XA05","category":"atc"},{"label":"Active","category":"status"},{"label":"Anemia in chronic kidney disease","category":"indication"},{"label":"Refractory anemia (clinical)","category":"indication"},{"label":"Astellas Pharma Europe B.V.","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Astellas Pharma Europe B.V.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ROXADUSTAT","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:33:33.637020+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:33:40.016104+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:33:33.705545+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ROXADUSTAT","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:33:40.393685+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Hypoxia-inducible factor prolyl hydroxylase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:33:41.597499+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2338329/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:33:41.250523+00:00"}},"allNames":"evrenzo","offLabel":[],"synonyms":["roxadustat","evrenzo","ASP 1517","AZD 9941","FG-4592"],"timeline":[{"date":"2019-09-20","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Astellas Pharma Inc.)"},{"date":"2021-08-18","type":"positive","source":"DrugCentral","milestone":"EMA approval (Astellas Pharma Europe B.V.)"}],"aiSummary":"Evrenzo (ROXADUSTAT) is a small molecule developed by Astellas Pharma Europe B.V. that targets the thyroid hormone receptor beta. It is used to treat anemia in chronic kidney disease and refractory anemia. The commercial status of Evrenzo is patented, and its safety considerations include potential effects on blood pressure and heart rate. Evrenzo works by mimicking the action of oxygen on the body, which helps to reduce the production of erythropoietin and subsequently decrease red blood cell production. Further clinical trials are needed to confirm its efficacy and safety.","approvals":[{"date":"2019-09-20","orphan":false,"company":"Astellas Pharma Inc.","regulator":"PMDA"},{"date":"2021-08-18","orphan":false,"company":"ASTELLAS PHARMA EUROPE B.V.","regulator":"EMA"}],"brandName":"Evrenzo","ecosystem":[{"indication":"Anemia in chronic kidney disease","otherDrugs":[{"name":"daprodustat","slug":"daprodustat","company":"Glaxosmithkline"},{"name":"epoetin alfa","slug":"epoetin-alfa","company":"Amgen"},{"name":"methoxy polyethylene glycol-epoetin beta","slug":"methoxy-polyethylene-glycol-epoetin-beta","company":"Hoffman-La Roche"},{"name":"nandrolone decanoate","slug":"nandrolone-decanoate","company":"Aspen Global Inc"}],"globalPrevalence":850000000},{"indication":"Refractory anemia (clinical)","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Thyroid hormone receptor beta","targets":[{"gene":"THRB","source":"DrugCentral","target":"Thyroid hormone receptor beta","protein":"Thyroid hormone receptor beta"},{"gene":"THRA","source":"DrugCentral","target":"Thyroid hormone receptor alpha","protein":"Thyroid hormone receptor alpha"},{"gene":"EGLN2","source":"DrugCentral","target":"Egl nine homolog 2","protein":"Egl nine homolog 2"},{"gene":"EGLN3","source":"DrugCentral","target":"Egl nine homolog 3","protein":"Egl nine homolog 3"},{"gene":"FTO","source":"DrugCentral","target":"Alpha-ketoglutarate-dependent dioxygenase FTO","protein":"Alpha-ketoglutarate-dependent dioxygenase FTO"},{"gene":"EGLN1","source":"DrugCentral","target":"Egl nine homolog 1","protein":"Egl nine homolog 1"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Evrenzo acts as a hypoxia-inducible factor prolyl hydroxylase inhibitor, which leads to the stabilization of hypoxia-inducible factor-alpha and subsequent reduction in erythropoietin production."},"commercial":{"revenueYear":2024,"annualRevenue":600,"revenueSource":"Verified: AstraZeneca AR","revenueCurrency":"USD","revenueConfidence":"verified","revenueExtractedAt":"2026-04-01T11:46:41.206242","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5371","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ROXADUSTAT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ROXADUSTAT","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T15:37:01.839294","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:33:42.800966+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"epoetin alfa","drugSlug":"epoetin-alfa","fdaApproval":"1989-06-01","relationship":"same-class"},{"drugName":"darbepoetin alfa","drugSlug":"darbepoetin-alfa","fdaApproval":"2001-09-17","relationship":"same-class"},{"drugName":"methoxy polyethylene glycol-epoetin beta","drugSlug":"methoxy-polyethylene-glycol-epoetin-beta","fdaApproval":"2007-11-14","relationship":"same-class"},{"drugName":"peginesatide","drugSlug":"peginesatide","fdaApproval":"2012-03-27","patentExpiry":"Jun 2, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"luspatercept","drugSlug":"luspatercept","fdaApproval":"2019-11-08","relationship":"same-class"},{"drugName":"daprodustat","drugSlug":"daprodustat","fdaApproval":"2023-02-01","patentExpiry":"Mar 13, 2038","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"roxadustat","indications":{"approved":[{"name":"Anemia in chronic kidney disease","source":"DrugCentral","snomedId":707323002,"regulator":"FDA","usPrevalence":37000000,"globalPrevalence":850000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet, 2023"},{"name":"Refractory anemia (clinical)","source":"DrugCentral","snomedId":109996008,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"epoetin-alfa","brandName":"epoetin alfa","genericName":"epoetin alfa","approvalYear":"1989","relationship":"same-class"},{"drugId":"darbepoetin-alfa","brandName":"darbepoetin alfa","genericName":"darbepoetin alfa","approvalYear":"2001","relationship":"same-class"},{"drugId":"methoxy-polyethylene-glycol-epoetin-beta","brandName":"methoxy polyethylene glycol-epoetin beta","genericName":"methoxy polyethylene glycol-epoetin beta","approvalYear":"2007","relationship":"same-class"},{"drugId":"peginesatide","brandName":"peginesatide","genericName":"peginesatide","approvalYear":"2012","relationship":"same-class"},{"drugId":"luspatercept","brandName":"luspatercept","genericName":"luspatercept","approvalYear":"2019","relationship":"same-class"},{"drugId":"daprodustat","brandName":"daprodustat","genericName":"daprodustat","approvalYear":"2023","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05970172","phase":"PHASE3","title":"A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2024-01-16","conditions":["Chronic Kidney Disease","Renal Anemia"],"enrollment":100,"completionDate":"2027-10-30"},{"nctId":"NCT07359027","phase":"PHASE4","title":"Study of Roxadustat's Effect on Anemia in Patients With Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2021-11-02","conditions":["Diabetic Kidney Disease","Anemia"],"enrollment":124,"completionDate":"2024-07-08"},{"nctId":"NCT07136792","phase":"NA","title":"A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-09-08","conditions":["Renal Anemia of Chronic Kidney Disease"],"enrollment":96,"completionDate":"2027-12"},{"nctId":"NCT05010460","phase":"PHASE2","title":"Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting","status":"TERMINATED","sponsor":"Peking Union Medical College Hospital","startDate":"2021-09-30","conditions":["Coronary Artery Bypass"],"enrollment":98,"completionDate":"2025-05-20"},{"nctId":"NCT07268807","phase":"","title":"Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease","status":"NOT_YET_RECRUITING","sponsor":"Zhongda Hospital","startDate":"2025-12-01","conditions":["Heart Failure","CKD","Anemia"],"enrollment":200,"completionDate":"2026-09-01"},{"nctId":"NCT07045155","phase":"PHASE4","title":"Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-08-01","conditions":["Dialysis; Complications","Chronic Kidney Disease 5D","Renal Anemia of Chronic Kidney Disease","Renal Anaemia","Renal Anemia, Chronic"],"enrollment":240,"completionDate":"2028-12-30"},{"nctId":"NCT07162090","phase":"PHASE4","title":"Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2025-09-10","conditions":["Sarcopenia","Anemia Associated With Chronic Kidney Disease (CKD)","Dialysis Patients"],"enrollment":60,"completionDate":"2026-12-31"},{"nctId":"NCT04408820","phase":"","title":"Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2020-06-01","conditions":["Renal Anemia"],"enrollment":2104,"completionDate":"2025-06-23"},{"nctId":"NCT04925661","phase":"PHASE1","title":"HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-11-04","conditions":["Chronic Kidney Diseases","Renal Anemia"],"enrollment":40,"completionDate":"2023-08-29"},{"nctId":"NCT06903559","phase":"PHASE1,PHASE2","title":"Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2025-04-15","conditions":["Kidney Failure, Chronic","Malnutrition-Inflammation Syndrome","Anemia in End Stage Renal Disease","Cardiovascular Diseases (CVD)"],"enrollment":46,"completionDate":"2025-11-01"},{"nctId":"NCT06917950","phase":"PHASE1,PHASE2","title":"Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2025-04-15","conditions":["Kidney Failure,Chronic","Anemia in End Stage Renal Disease","Depression Anxiety Disorder"],"enrollment":46,"completionDate":"2025-11-01"},{"nctId":"NCT06772272","phase":"PHASE3","title":"Effect of Perioperative Roxadustat in Elective Lumbar Interbody Fusion Surgery.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-11-10","conditions":["Perioperative Anemia"],"enrollment":158,"completionDate":"2027-05-10"},{"nctId":"NCT02278341","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-11-21","conditions":["Anemia","End Stage Renal Disease (ESRD)"],"enrollment":838,"completionDate":"2018-07-06"},{"nctId":"NCT05810311","phase":"PHASE2","title":"The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Region Stockholm","startDate":"2025-06-01","conditions":["Diabetes Complications","Diabetes; Nephropathy (Manifestation)"],"enrollment":30,"completionDate":"2027-12-31"},{"nctId":"NCT01887600","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-09-03","conditions":["Anemia in Chronic Kidney Disease in Non-dialysis Patients"],"enrollment":594,"completionDate":"2017-11-01"},{"nctId":"NCT02021318","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-03-12","conditions":["Anemia in Chronic Kidney Disease in Non-dialysis Patients"],"enrollment":616,"completionDate":"2019-11-06"},{"nctId":"NCT02964936","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-01-11","conditions":["Chronic Kidney Disease"],"enrollment":100,"completionDate":"2018-08-15"},{"nctId":"NCT02988973","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-01-12","conditions":["Chronic Kidney Disease"],"enrollment":334,"completionDate":"2020-03-26"},{"nctId":"NCT03960489","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2019-07-31","conditions":["Healthy Adult Subjects"],"enrollment":24,"completionDate":"2019-10-14"},{"nctId":"NCT02779764","phase":"PHASE3","title":"A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-05-16","conditions":["Hemodialysis Patients With Renal Anemia"],"enrollment":164,"completionDate":"2017-11-28"},{"nctId":"NCT02780141","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-06-02","conditions":["ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia"],"enrollment":75,"completionDate":"2017-12-12"},{"nctId":"NCT02952092","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-11-30","conditions":["Hemodialysis Chronic Kidney Disease Patients With Anemia"],"enrollment":303,"completionDate":"2018-03-15"},{"nctId":"NCT01083888","phase":"PHASE1","title":"ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-02-15","conditions":["Anemia","Hemodialysis","Renal Impairment"],"enrollment":12,"completionDate":"2010-06-07"},{"nctId":"NCT02780726","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-06-22","conditions":["Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia"],"enrollment":56,"completionDate":"2017-08-02"},{"nctId":"NCT01888445","phase":"PHASE2","title":"A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-03-28","conditions":["Renal Anemia Associated With Chronic Renal Failure (CRF)"],"enrollment":130,"completionDate":"2014-09-15"},{"nctId":"NCT03263091","phase":"PHASE3","title":"Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden","status":"TERMINATED","sponsor":"Kyntra Bio","startDate":"2018-01-29","conditions":["Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)","Anemia"],"enrollment":184,"completionDate":"2023-06-20"},{"nctId":"NCT04655027","phase":"PHASE4","title":"A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-02-22","conditions":["Anemia of Chronic Kidney Disease"],"enrollment":25,"completionDate":"2021-10-12"},{"nctId":"NCT06287879","phase":"NA","title":"Function and Morphological Characteristics of Meibomian Gland in Patients With Renal Anemia","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2023-04-01","conditions":["Dry Eye","MGD-Meibomian Gland Dysfunction"],"enrollment":50,"completionDate":"2024-12-30"},{"nctId":"NCT06115421","phase":"PHASE4","title":"Effect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2023-05-24","conditions":["Anemia in Dialysis-dependent CKD Patients"],"enrollment":72,"completionDate":"2024-05"},{"nctId":"NCT06020833","phase":"PHASE1,PHASE2","title":"A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-08","conditions":["Myelodysplastic Syndromes"],"enrollment":25,"completionDate":"2026-12"},{"nctId":"NCT06006949","phase":"PHASE4","title":"Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-08","conditions":["Myelodysplastic Syndromes"],"enrollment":62,"completionDate":"2025-08"},{"nctId":"NCT05301517","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2022-03-16","conditions":["Chemotherapy Induced Anemia"],"enrollment":159,"completionDate":"2023-04-21"},{"nctId":"NCT03303066","phase":"PHASE2,PHASE3","title":"Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2018-06-06","conditions":["Anemia","Myelodysplastic Syndrome"],"enrollment":43,"completionDate":"2023-02-08"},{"nctId":"NCT05691257","phase":"PHASE4","title":"Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia","status":"UNKNOWN","sponsor":"China-Japan Friendship Hospital","startDate":"2023-02-01","conditions":["Heart Failure","Chronic Kidney Diseases","Anemia"],"enrollment":300,"completionDate":"2023-12-01"},{"nctId":"NCT04410198","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-05-26","conditions":["Anemia Associated With End Stage Renal Disease (ESRD)"],"enrollment":203,"completionDate":"2021-10-11"},{"nctId":"NCT04484857","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-07-22","conditions":["Anemia Associated With End Stage Renal Disease"],"enrollment":283,"completionDate":"2021-09-17"},{"nctId":"NCT04621331","phase":"PHASE3","title":"Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD","status":"WITHDRAWN","sponsor":"Kyntra Bio","startDate":"2022-05-23","conditions":["Anemia Associated With Chronic Kidney Disease"],"enrollment":0,"completionDate":"2022-05-23"},{"nctId":"NCT04076943","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2019-08-20","conditions":["Chemotherapy Induced Anemia"],"enrollment":92,"completionDate":"2021-04-23"},{"nctId":"NCT04059913","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2019-06-11","conditions":["CKD Anemia in Dialysis Participants"],"enrollment":318,"completionDate":"2021-12-17"},{"nctId":"NCT01244763","phase":"PHASE2","title":"Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2010-10-29","conditions":["Chronic Kidney Disease","Anemia"],"enrollment":145,"completionDate":"2012-06-13"},{"nctId":"NCT01147666","phase":"PHASE2","title":"Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2010-05-17","conditions":["End Stage Renal Disease","Anemia"],"enrollment":161,"completionDate":"2012-10-15"},{"nctId":"NCT04454879","phase":"PHASE4","title":"Different Doses of Roxadustat Treatment for Anemia in Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2020-07-01","conditions":["Renal Anemia"],"enrollment":100,"completionDate":"2021-08-03"},{"nctId":"NCT00761657","phase":"PHASE2","title":"Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2006-11-01","conditions":["Chronic Kidney Disease","Anemia"],"enrollment":117,"completionDate":"2010-06-21"},{"nctId":"NCT02273726","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2015-01-15","conditions":["CKD Anemia in Stable Dialysis Patients"],"enrollment":741,"completionDate":"2018-09-19"},{"nctId":"NCT01414075","phase":"PHASE2","title":"Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2011-07-21","conditions":["Dialysis","Anemia"],"enrollment":60,"completionDate":"2013-01-10"},{"nctId":"NCT02052310","phase":"PHASE3","title":"Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2014-02-11","conditions":["Anemia in Incident Dialysis Patients"],"enrollment":1043,"completionDate":"2018-09-21"},{"nctId":"NCT01630889","phase":"PHASE2","title":"Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2012-05-18","conditions":["Chronic Kidney Disease","End Stage Renal Disease","Anemia"],"enrollment":15,"completionDate":"2019-12-12"},{"nctId":"NCT01750190","phase":"PHASE3","title":"A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2012-11-05","conditions":["CKD Anemia"],"enrollment":922,"completionDate":"2018-09-24"},{"nctId":"NCT05053893","phase":"NA","title":"Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2021-09-22","conditions":["Cardio-Renal Syndrome"],"enrollment":40,"completionDate":"2022-09-01"},{"nctId":"NCT04803864","phase":"PHASE2","title":"Study of Roxadustat in the Treatment of Acute Myocardial Infarction","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-06-10","conditions":["ST Elevation Myocardial Infarction"],"enrollment":158,"completionDate":"2023-08-31"},{"nctId":"NCT04925011","phase":"PHASE3","title":"Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD","status":"UNKNOWN","sponsor":"Mao Jianhua","startDate":"2021-09-01","conditions":["Anemia Associated With Chronic Kidney Disease"],"enrollment":30,"completionDate":"2022-12-30"},{"nctId":"NCT04502537","phase":"","title":"Roxadustat for Anemia in Patients With CKD","status":"UNKNOWN","sponsor":"Shenzhen Second People's Hospital","startDate":"2021-02-01","conditions":["Anemia of Chronic Kidney Disease"],"enrollment":200,"completionDate":"2023-09-30"},{"nctId":"NCT02965040","phase":"PHASE1","title":"A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2016-12-12","conditions":["Normal Renal Function","Impaired Renal Function"],"enrollment":34,"completionDate":"2017-12-11"},{"nctId":"NCT02174627","phase":"PHASE3","title":"Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-26","conditions":["Anemia"],"enrollment":2781,"completionDate":"2018-10-04"},{"nctId":"NCT02174731","phase":"PHASE3","title":"Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-07-01","conditions":["Anemia"],"enrollment":2133,"completionDate":"2018-09-26"},{"nctId":"NCT02652806","phase":"PHASE3","title":"FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2015-12","conditions":["Anemia"],"enrollment":305,"completionDate":"2017-06-14"},{"nctId":"NCT02652819","phase":"PHASE3","title":"FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2015-12","conditions":["Anemia"],"enrollment":154,"completionDate":"2017-06-13"},{"nctId":"NCT02252731","phase":"PHASE1","title":"A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-09","conditions":["Pharmacokinetics of FG-4592","Healthy Subjects"],"enrollment":22,"completionDate":"2013-11"},{"nctId":"NCT02161796","phase":"PHASE1","title":"A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-09","conditions":["PK for FG-4592","Healthy Subjects"],"enrollment":48,"completionDate":"2013-12"},{"nctId":"NCT02161224","phase":"PHASE1","title":"A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-09","conditions":["PK of FG-4592","Hepatic Insufficiency","Healthy Subjects"],"enrollment":16,"completionDate":"2013-12"},{"nctId":"NCT01599507","phase":"PHASE2","title":"Study of FG-4592 in Subjects With Chronic Kidney Disease in China","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2011-12","conditions":["Anemia in Chronic Kidney Disease"],"enrollment":91,"completionDate":"2013-01"},{"nctId":"NCT01596855","phase":"PHASE2","title":"Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2011-09","conditions":["Anemia in End Stage Renal Disease"],"enrollment":96,"completionDate":"2013-01"},{"nctId":"NCT01376063","phase":"PHASE1","title":"Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2010-03","conditions":["Healthy Adult Subjects"],"enrollment":20,"completionDate":"2010-06"},{"nctId":"NCT00978198","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male Volunteers","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-09","conditions":["Healthy Volunteers"],"enrollment":100,"completionDate":"2010-06"}],"_emaApprovals":[{"date":"2021-08-18","status":"Authorised","company":"ASTELLAS PHARMA EUROPE B.V."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"018888","UNII":"X3O30D9YMX","CHEBI":"CHEBI:132774","INN_ID":"9717","UMLSCUI":"C4310578","chemblId":"CHEMBL2338329","ChEMBL_ID":"CHEMBL2338329","KEGG_DRUG":"D10593","DRUGBANK_ID":"DB04847","PDB_CHEM_ID":"8HO","PUBCHEM_CID":"11256664","IUPHAR_LIGAND_ID":"8454","MESH_SUPPLEMENTAL_RECORD_UI":"C584543"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Astellas Pharma Europe B.V.","relationship":"Original Developer"},{"period":"2019","companyName":"Astellas Pharma Inc.","relationship":"PMDA Licensee"}],"publicationCount":535,"therapeuticAreas":["Hematology"],"_revenueScrapedAt":"2026-04-08 13:57:45.235675+00","atcClassification":{"source":"DrugCentral","atcCode":"B03XA05","allCodes":["B03XA05"]},"biosimilarFilings":[],"originalDeveloper":"Astellas Pharma Europe B.V.","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Astellas Pharma Europe B.V.","companyId":"astellas","modality":"Small molecule","firstApprovalDate":"2021","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2019-09-20T00:00:00.000Z","mah":"Astellas Pharma Inc.","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:33:42.800966+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}